Rhythm Pharmaceuticals (RYTM) Misses Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results
May 14, 2018 8:00 AM EDT-- U.S. Food and Drug Administration (FDA) Agreed that Bardet-Biedl Syndrome (BBS) and Alström Syndrome are Included Under Existing Breakthrough Therapy Designation (BTD) for Setmelanotide --
-- Entered Licensing Agreement with Takeda for RM-853, Currently in Preclinical Development for Prader-Willi Syndrome (PWS); Investigational New Drug Application (IND) expected to be Filed in First Quarter of 2020 --
BOSTON, May 14, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare... More
